Alzheimers Dement. 2025 Sep;21(9): e70730
Tong-Yao Gao,
Xu-Zheng Wang,
Yu-Han Xie,
Tong Wang,
Yun-Bi Lu,
Lu-Long Huang,
Cong Chen,
Ming Zhang,
Xin Ma,
Ya-Ling Chen,
Fu-Xiang Liang,
Zhi-Ling Lou,
Jin-Sheng Li,
Yi-Fan Yu,
Jian-Bin Wu,
Xiao-Ru Ma,
Hua-Li Wang,
Chun Tang,
Wei-Ping Zhang.
INTRODUCTION: Dementia with Lewy bodies (DLB), a prevalent neurodegenerative dementia, involves α-synuclein (α-syn) aggregates and frequent amyloid beta (Aβ) co-pathology, but mechanistic drivers remain unclear.
METHODS: We crossed pink1 knockout with APP/PS1 mice, and assessed behavioral and pathological phenotypes of the resulting animals. We also performed biochemical and biophysical characterizations of PTEN-induced kinase 1 (PINK1) phosphorylation of α-syn.
RESULTS: DLB brains show PINK1 deficiency alongside α-syn and Aβ co-pathology. Mirroring human DLB patients, APP/PS1::pink1-/- mice spontaneously develop Lewy pathology at endogenous α-syn levels, affecting both central and peripheral nervous systems with heterogeneous phenotypes. Mechanistically, PINK1 phosphorylates α-syn at Thr44, suppressing Aβ-induced α-syn aggregation. Moreover, pT44-α-syn levels are correlated with PINK1 expression and activity in human brains.
DISCUSSION: PINK1 deficiency synergizes with Aβ to promote Lewy pathology via loss of protective α-syn phosphorylation. The APP/PS1::pink1-/- model recapitulates key DLB features without α-syn overexpression, offering a valuable tool for future mechanistic and therapeutic studies.
HIGHLIGHTS: PTEN-induced kinase 1 (PINK1) deficiency, either through reduced expression or impaired activity, is found in human dementia with Lewy bodies (DLB) patients with amyloid beta (Aβ) co-pathology. PINK1 specifically phosphorylates α-synuclein at Thr44, inhibiting Aβ-induced aggregation and preventing the development of Lewy pathology. The APP/PS1::pink1-/- mouse model recapitulates key features of human DLB, exhibiting widespread Lewy pathology and heterogeneous phenotypes. PINK1 alterations emerge as a novel genetic risk factor for DLB, opening new avenues for diagnosis and therapeutic intervention.
Keywords: APP/PS1 mouse; Alzheimer's disease; Lewy body; Lewy neurite; PTEN‐induced kinase 1; Parkinson's disease; amyloid beta; dementia with Lewy bodies; phosphorylation; α‐synuclein